Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Lineage Cell Therapeutics Inc LCTX

Healthcare Biotechnology
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an... see more

Current News (NYSEAM:LCTX)

Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Business Wire November 6, 2025

Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Business Wire October 30, 2025

Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes

Business Wire September 8, 2025

Lineage Cell Therapeutics to Present at September 2025 Investor Conferences

Business Wire September 2, 2025

Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance(TM) (ANP1) for Hearing Loss

Business Wire August 26, 2025

Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Business Wire August 12, 2025

Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

Business Wire August 5, 2025

Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury

Business Wire August 4, 2025

OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025

Business Wire June 23, 2025
View More News ››

Opinion & Analysis (NYSEAM:LCTX)

Canada Fluorspar (V.CFI) up 11% on Grebes Nest results

Stockhouse Editorial August 29, 2013
View More Opinion ››

Bullboard Posts (NYSEAM:LCTX)

Lineage Cell Therapeutics, Inc. (LCTX): Advancing Groundbrea

http://beyondspx.com/2024/08/01/lineage-cell-therapeutics-inc-lctx-advancing-groundbreaking-cell-therapies-with-promising-clinical-data...
MikeTester - August 1, 2024

RE:Lineage Cell Therapeutics Announces Closing of $14.0 Million

Why the bounce today?
Teccing - March 27, 2024

starting to look really good!

So we have a catalyst Q1/Q2 2021 on Dry AMD. A $10B market with no solution and LCTX might be the answer! I'm Long in BTI.V, LCTX...
unclepieman - January 11, 2021

TODAY 1PM - Meet CEO Brian Culley and CFO Brandi Roberts

**TODAY** - Nov 10th - virtual road show today with CEO Brian Culley and CFO Brandi Roberts. Register at no charge: https...
schoolofrock - November 10, 2020

Nov 10th - Meet CEO Brian Culley and CFO Brandi Roberts

Mark your calendar - Nov 10th - virtual road show a week from today with CEO Brian Culley and CFO Brandi Roberts. Register at no charge: ...
schoolofrock - November 3, 2020

LCTX - Early VAC2 Data Shows Promise

Lineage disclosed data from the Phase 1 clinical study of VAC2 for the treatment of non-small cell lung cancer (NSCLC), sponsored by...
schoolofrock - October 14, 2020
View more Bullboard ››

Southern Silver Exploration Corp.

Southern Silver Exploration Corp.

Southern Silver Exploration Corp., an exploration stage company, acquires, explores, and develops natural resource properties ...
View More »